Therapeutic options for digital ulcers in patients with systemic sclerosis;Therapeutische optionen für digitale ulzera bei patienten mit systemischer sklerodermie

JDDG - Journal of the German Society of Dermatology

Volumn 5, Issue 6, 2007, Pages 460-465

  Chung, Lorinda ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Digital ulcers; Raynaud phenomenon; Systemic sclerosis

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; BERAPROST; BOSENTAN; DIPYRIDAMOLE; GLYCERYL TRINITRATE; ILOPROST; LIDOCAINE; LOSARTAN; MQX 503; NIFEDIPINE; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; OPC 28326; PARACETAMOL; PLACEBO; PRAZOSIN; PROSTACYCLIN; SILDENAFIL; UNCLASSIFIED DRUG; UNIPROST; UROKINASE;

CLINICAL TRIAL; COLD; COLD CLIMATE; DIGITAL ULCER; DISEASE ASSOCIATION; DRUG DOSE INCREASE; HEADACHE; HEALTH EDUCATION; HUMAN; HYDROCOLLOID DRESSING; INJURY; ISCHEMIA; PAIN; PATHOGENESIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; RISK FACTOR; SKIN ULCER; SMOKING CESSATION; STRESS; SURGICAL TECHNIQUE; SYSTEMIC SCLEROSIS; WOUND CARE;

EID: 34250314990     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2007.06279.x     Document Type: Review

References (51)

1. Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001; 357: 2042-2048.
2. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jimenez SA, White B, Seibold JR, Wigley FM. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46(9): 2410-2420.
3. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, Bullo A, Cazzato M, Tirri E, Storino F, giuggioli D, Cuomo G, Rosada M, Bombardieri S, Todesco S, Tirri G. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002; 81(2): 139-153.
4. Ostojic P, Damjanov N, Pavlov-Dolijanovic S, Radunovic G. Peripheral vasculopathy in patients with systemic sclerosis: difference in limited and diffuse subset of disease. Clin Hemorheol and Microcirc 2004; 31(4): 281-285.
5. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis and Rheum 2005; 35(1): 35-42.
6. Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, Fritzler MJ, Ahn C, Arnett FC. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001; 30(5): 332-346.
7. Nietert PJ, Mitchell HC, Bolster MB, Shaftman SR, Tilley BC, Silver RM. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol 2006; 33(2): 263-268.
8. Hummers LK, Wigley FM. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 2003; 29(2): 293-313.
9. Flavahan NA, Flavahan S, Liu Q, Wu S, Tidmore W, Wiener CM, Spence RJ, Wigley FM. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000; 43(8): 1886-1890.
10. Pignone A, Scaletti C, Matucci-Cerinic M, Vazquez-Abad D, Meroni PL, Del Papa N, Falcini F, Generini S, Rothfield N, Cagnoni M. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 1998; 16(5): 527-532.
11. Salojin KV, Le Tonquèze M, Saraux A, Nassonov EL, Dueymes M, Piette JC, Youinou PY. Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 1997; 102(2): 178-185.
12. Negi VS, Tripathy NK, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998; 25(3): 462-466.
13. Worda M, Sgonc R, Dietrich H, Niederegger H, Sundick RS, Gershwin ME, Wick G. In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum 2003; 48(9): 2605-2614.
14. Cooke J, Marshall J. Mechanisms of Raynaud's disease. Vascular Medicine 2005; 10: 293-307.
15. Allanore Y, Borderie D, Meune C, Lemarechal H, Weber S, Ekindjian OG, Kahan A. Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. Ann Rheum Dis 2005; 64(3): 481-483.
16. Milburn PB, Singer JZ, Milburn MA. Treatment of scleroderma skin ulcers with a hydrocolloid membrane. J Am Acad Dermatol 1989; 21(2 Pt 1): 200-204.
17. Yoon J, Giacopelli J, Granoff D, Kobayashi W. Treatment of scleroderma skin ulcers using becaplermin gel and hydrocolloid membrane. J Am Podiatr Med Assoc 2002; 92(6): 350-354.
18. Filho JP, Sampaio-Barros PD, Parente JB, Menezes FH, Poterio GB, Samara AM, Marques Neto JF. Rhythmic external compression of the limbs: a method for healing cutaneous ulcers in systemic sclerosis. J Rheumatol 1998; 25(8): 1540-1543.
19. Markus YM, Bell MJ, Evans AW. Ischemic scleroderma wounds successfully treated with hyperbaric oxygen therapy. J Rheumatol 2006; 33(8): 1694-1696.
20. Ozgocmen S, Kaya A, Coskun BK. Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma). Clin Rheumatol 2006; 25(3): 378-379.
21. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001; 44(8): 1841-1847.
22. Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, Kirby JD. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 1989; 298(6673): 561-564.
23. Surwit RS, Gilgor RS, Allen LM, Duvic M. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma. Arch Dermatol 1984; 120(3): 329-331.
24. Russell IJ, Lessard JA. Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study. The J Rheumatol 1985; 12(1): 94-98.
25. Wise RA, Wigley FM, White B, Leatherman G, Zhong J, Krasa H, Kambayashi J, Orlandi C, Czerwiec FS. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a singlecenter, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 2004; 50(12): 3994-4001.
26. Challenor VF. Angiotensin converting enzyme inhibitors in Raynaud's phenomenon. Drugs 1994; 48(6): 864-867.
27. Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999; 42(12): 2646-2655.
28. Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001; 40(9): 1038-1043.
29. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132(6): 425-434.
30. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992; 19(9): 1407-1414.
31. Zachariae H, Halkier-Sørensen L, Bjerring P, Heickendorff L. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis. Acta Derm Venereol 1996; 76(3): 236-238.
32. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, Steen VD, Varga J, Jimenez S, Mayes M, Clements PJ, Weiner SR, Porter J, Ellman M, Wise C, Kaufman LD, Williams J, Dole W. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994; 120(3): 199-206.
33. Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998; 41(4): 670-677.
34. Black CM, Halkier-Sørensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, Banga JD, Watson HR. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 1998; 37(9): 952-960.
35. Vayssairat M. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes. J Rheumatol 1996; 23(11): 1917-1920.
36. Chung L, Fiorentino D. A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J Am Acad of Dermatol 2006; 54(5): 880-882.
37. Jain M, Varga J. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers. Expert opinion on pharmacotherapy 2006; 7(11): 1487-1501.
38. Ramos-Casals M, Brito-Zerón P, Nardi N, Claver G, Risco G, Parraga FD, Fernandez S, Julia M, Font J. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology 2004; 43(11): 1454-1456.
39. Launay D, Diot E, Pasquier E, Mouthon L, Boullanger N, Fain O, Jego P, Carpentier P, Hatron PY, Hachulla E . Bosentan for treatment of active digital ulcers in patients with systemic sclerosis Press Med. 2006; 35(4 Pt 1): 587-592.
40. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Moliter J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C . Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50(12):3985-3993.
41. Siebold J. Bosentan prevents occurrence but does not speed the healing of digital ulcers in patients with systemic sclerosis. Arthritis Rheum 2005;L2:552(Abstract).
42. Gore J, Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 2005; 64(9): 1387.
43. Colglazier CL, Sutej PG, O'Rourke KS. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. J Rheumatol 2005; 32(12): 2440-2442.
44. Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005; 112(19): 2980-2985.
45. Beckett VL, Conn DL, Fuster V, Osmundson PJ, Strong CG, Chao EY, Chesebro JH, O'Fallon WM. Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum 1984; 27(10): 1137-1143.
46. Denton CP, Howell K, Stratton RJ, Black CM. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. Clin Exp Rheumatol 2000; 18(4): 499-502.
47. Ciompi ML, Bazzichi L, Melchiorre D, De Giorgio F, Bondi F, Puccetti L. A placebo-controlled study on urokinase therapy in systemic sclerosis. Biomedicine & pharmacotherapy 1996; 50(8): 363-368.
48. Sambo P, Amico D, Giacomelli R, Matucci-Cerinic M, Salsano F, Valentini G, Gabrielli A. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 2001; 28(10): 2257-2262.
49. Kuwana M, Kaburaki J, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 2006; 54(6): 1946-1951.
50. Bogoch ER, Gross DK. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol 2005; 32(4): 642-648.
51. Ruch DS, Holden M, Smith BP, Smith TL, Koman LA. Periarterial sympathectomy in scleroderma patients: intermediate-term follow-up. J Hand Surg 2002; 27(2): 258-264.